{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T05:46:12Z","timestamp":1775627172358,"version":"3.50.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T00:00:00Z","timestamp":1770768000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T00:00:00Z","timestamp":1772755200000},"content-version":"vor","delay-in-days":23,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100017346","name":"Nippon Boehringer Ingelheim Co., Ltd.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100017346","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-38944-3","type":"journal-article","created":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T15:53:04Z","timestamp":1770825184000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and safety findings of the EXTRA study in older adult EGFR-mutant lung cancer patients receiving afatinib as first-line treatment"],"prefix":"10.1038","volume":"16","clinical-trial-number":[{"clinical-trial-number":"umin000024935","registry":"10.18810\/umin-japan"}],"author":[{"given":"Kei","family":"Morikawa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saori","family":"Takata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hisashi","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidetoshi","family":"Itani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masashi","family":"Ishihara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuya","family":"Horiuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhiro","family":"Kato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinnosuke","family":"Ikemura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideyuki","family":"Nakagawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiro","family":"Nakahara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshitaka","family":"Seki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihiro","family":"Bessho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobumasa","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kentaro","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeo","family":"Endoh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiyoshi","family":"Takeyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiya","family":"Maekura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nagio","family":"Takigawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akikazu","family":"Kawase","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makoto","family":"Endoh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenji","family":"Nemoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuma","family":"Kishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenzo","family":"Soejima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke","family":"Okuma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenichi","family":"Yoshimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisuke","family":"Saigusa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yae","family":"Kanai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Ueda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Togashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriyuki","family":"Matsutani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuhiko","family":"Seki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,11]]},"reference":[{"key":"38944_CR1","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1001\/jama.2014.3741","volume":"311","author":"MG Kris","year":"2014","unstructured":"Kris, M. G. et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA 311, 1998\u20132006 (2014).","journal-title":"JAMA"},{"key":"38944_CR2","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.3390\/cancers12041009","volume":"12","author":"V Gambardella","year":"2020","unstructured":"Gambardella, V. et al. Personalized medicine: Recent progress in cancer therapy. Cancers 12, 1009 (2020).","journal-title":"Cancers"},{"key":"38944_CR3","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1016\/j.annonc.2020.07.014","volume":"31","author":"F Mosele","year":"2020","unstructured":"Mosele, F. et al. Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: A report from the ESMO precision medicine working group. Ann. Oncol. 31, 1491\u20131505 (2020).","journal-title":"Ann. Oncol."},{"key":"38944_CR4","first-page":"567","volume":"31","author":"Y Nishiwaki","year":"2004","unstructured":"Nishiwaki, Y. et al. Subset analysis of data in the Japanese patients with NSCLC from IDEAL 1 study on gefitinib. Gan To Kagaku Ryoho 31, 567\u2013573 (2004).","journal-title":"Gan To Kagaku Ryoho"},{"key":"38944_CR5","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1056\/NEJMoa0810699","volume":"361","author":"TS Mok","year":"2009","unstructured":"Mok, T. S. et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med. 361, 947\u2013957 (2009).","journal-title":"N. Engl. J. Med."},{"key":"38944_CR6","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1097\/JTO.0b013e318260de8b","volume":"7","author":"M Maemondo","year":"2012","unstructured":"Maemondo, M. et al. First-line gefitinib in patients aged 75 or older with advanced non-small cell lung cancer harboring epidermal growth factor receptor mutations: NEJ 003 study. J. Thorac. Oncol. 7, 1417\u20131422 (2012).","journal-title":"J. Thorac. Oncol."},{"key":"38944_CR7","doi-asserted-by":"publisher","first-page":"2350","DOI":"10.1200\/JCO.2007.15.2280","volume":"26","author":"P Wheatley-Price","year":"2008","unstructured":"Wheatley-Price, P., Ding, K., Seymour, L., Clark, G. M. & Shepherd, F. A. Erlotinib for advanced non-small-cell lung cancer in the elderly: an analysis of the national cancer institute of canada clinical trials group study Br.21. J. Clin. Oncol. 26, 2350\u20132357 (2008).","journal-title":"J. Clin. Oncol."},{"key":"38944_CR8","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.lungcan.2014.09.015","volume":"86","author":"H Yoshioka","year":"2014","unstructured":"Yoshioka, H. et al. Efficacy and safety of erlotinib in elderly patients in the phase IV polarstar surveillance study of Japanese patients with non-small-cell lung cancer. Lung Cancer 86, 201\u2013206 (2014).","journal-title":"Lung Cancer"},{"key":"38944_CR9","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1111\/ggi.14313","volume":"22","author":"M Mineshita","year":"2022","unstructured":"Mineshita, M. et al. Flexible bronchoscopy for lung cancer diagnosis in patients aged \u226585 years. Geriatr. Gerontol. Int. 22, 32\u201335 (2022).","journal-title":"Geriatr. Gerontol. Int."},{"key":"38944_CR10","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1164\/rccm.200710-1501OC","volume":"177","author":"S Kudoh","year":"2008","unstructured":"Kudoh, S. et al. Interstitial lung disease in Japanese patients with lung cancer: A cohort and nested case-control study. Am. J. Respir. Crit. Care Med. 177, 1348\u20131357 (2008).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"38944_CR11","doi-asserted-by":"publisher","first-page":"2549","DOI":"10.1200\/JCO.2005.04.9866","volume":"24","author":"M Ando","year":"2006","unstructured":"Ando, M. et al. Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib. J. Clin. Oncol. 24, 2549\u20132556 (2006).","journal-title":"J. Clin. Oncol."},{"key":"38944_CR12","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1056\/NEJMoa1913662","volume":"382","author":"SS Ramalingam","year":"2020","unstructured":"Ramalingam, S. S. et al. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N. Engl. J. Med. 382, 41\u201350 (2020).","journal-title":"N. Engl. J. Med."},{"key":"38944_CR13","unstructured":"Nogami, N., et al. Osimertinib as first-line therapy for EGFRm advanced NSCLC (FLAURA): Final OS in Japanese subset in the 60th annual meeting of the Japan lung cancer society. https:\/\/www.haigan.gr.jp\/journal\/am\/2019a\/19a_pdsy0000PS-1.html;2019."},{"key":"38944_CR14","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1200\/JCO.19.01488","volume":"38","author":"Y Hosomi","year":"2020","unstructured":"Hosomi, Y. et al. Gefitinib alone versus gefitinib plus chemotherapy for non-small-cell lung cancer with mutated epidermal growth factor receptor: NEJ009 study. J. Clin. Oncol. 38, 115\u2013123 (2020).","journal-title":"J. Clin. Oncol."},{"key":"38944_CR15","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/S2213-2600(21)00166-1","volume":"10","author":"Y Kawashima","year":"2022","unstructured":"Kawashima, Y. et al. Bevacizumab plus erlotinib versus erlotinib alone in Japanese patients with advanced, metastatic, EGFR-mutant non-small-cell lung cancer (NEJ026): Overall survival analysis of an open-label, randomised, multicentre, phase 3 trial. Lancet Respir. Med. 10, 72\u201382 (2022).","journal-title":"Lancet Respir. Med."},{"key":"38944_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2023.107426","volume":"186","author":"Y Sakata","year":"2023","unstructured":"Sakata, Y. et al. Osimertinib as first-line treatment for elderly patients with advanced EGFR mutation-positive non-small cell lung cancer in a real-world setting (OSI-FACT-EP). Lung Cancer 186, 107426 (2023).","journal-title":"Lung Cancer"},{"key":"38944_CR17","doi-asserted-by":"publisher","first-page":"23140","DOI":"10.1038\/s41598-021-02561-z","volume":"11","author":"G Yamamoto","year":"2021","unstructured":"Yamamoto, G. et al. First-line osimertinib in elderly patients with epidermal growth factor receptor-mutated advanced non-small cell lung cancer: A retrospective multicenter study (HOT2002). Sci. Rep. 11, 23140 (2021).","journal-title":"Sci. Rep."},{"key":"38944_CR18","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1186\/s12885-021-07861-1","volume":"21","author":"Y Minegishi","year":"2021","unstructured":"Minegishi, Y. et al. A phase II study of first-line afatinib for patients aged \u226575 years with EGFR mutation-positive advanced non-small cell lung cancer: North East Japan study group trial NEJ027. BMC Cancer 21, 208 (2021).","journal-title":"BMC Cancer"},{"key":"38944_CR19","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.lungcan.2018.10.014","volume":"126","author":"H Imai","year":"2018","unstructured":"Imai, H. et al. A phase II study of afatinib treatment for elderly patients with previously untreated advanced non-small-cell lung cancer harboring EGFR mutations. Lung Cancer 126, 41\u201347 (2018).","journal-title":"Lung Cancer"},{"key":"38944_CR20","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1111\/1759-7714.12923","volume":"10","author":"Y Okuma","year":"2019","unstructured":"Okuma, Y. et al. Prospective exosome-focused translational research for afatinib study of non-small cell lung cancer patients expressing EGFR (EXTRA study). Thorac. Cancer 10, 395\u2013400 (2019).","journal-title":"Thorac. Cancer"},{"key":"38944_CR21","doi-asserted-by":"publisher","first-page":"175883592311770","DOI":"10.1177\/17588359231177021","volume":"15","author":"S Takata","year":"2023","unstructured":"Takata, S. et al. Prospective exosome-focused translational research for afatinib (EXTRA) study of patients with non-small cell lung cancer harboring EGFR mutation: An observational clinical study. Ther. Adv. Med. Oncol. 15, 17588359231177020 (2023).","journal-title":"Ther. Adv. Med. Oncol."},{"key":"38944_CR22","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1111\/cas.12723","volume":"106","author":"T Kato","year":"2015","unstructured":"Kato, T. et al. Afatinib versus cisplatin plus pemetrexed in Japanese patients with advanced non-small cell lung cancer harboring activating EGFR mutations: Subgroup analysis of LUX-Lung 3. Cancer Sci. 106, 1202\u20131211 (2015).","journal-title":"Cancer Sci."},{"key":"38944_CR23","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1093\/oncolo\/oyac193","volume":"27","author":"Y Chihara","year":"2022","unstructured":"Chihara, Y. et al. A phase II trial on osimertinib as a first-line treatment for EGFR mutation-positive advanced NSCLC in elderly patients: the SPIRAL-0 study. Oncologist 27, 903-e834 (2022).","journal-title":"Oncologist"},{"key":"38944_CR24","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.lungcan.2019.03.030","volume":"135","author":"T Yokoyama","year":"2019","unstructured":"Yokoyama, T. et al. A phase II study of low starting dose of afatinib as first-line treatment in patients with EGFR mutation-positive non-small-cell lung cancer (KTORG1402). Lung Cancer 135, 175\u2013180 (2019).","journal-title":"Lung Cancer"},{"key":"38944_CR25","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1016\/S1470-2045(19)30634-5","volume":"20","author":"K Nakagawa","year":"2019","unstructured":"Nakagawa, K. et al. Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 20, 1655\u20131669 (2019).","journal-title":"Lancet Oncol."},{"key":"38944_CR26","doi-asserted-by":"publisher","first-page":"e257","DOI":"10.1016\/j.cllc.2021.10.007","volume":"23","author":"N Haratake","year":"2022","unstructured":"Haratake, N. et al. Phase III clinical trial for the combination of erlotinib plus ramucirumab compared with osimertinib in previously untreated advanced or recurrent non-small cell lung cancer positive for the L858R mutation of EGFR: REVOL858R (WJOG14420L). Clin. Lung Cancer 23, e257\u2013e263 (2022).","journal-title":"Clin. Lung Cancer"},{"key":"38944_CR27","doi-asserted-by":"publisher","first-page":"175883592096725","DOI":"10.1177\/1758835920967254","volume":"12","author":"K Morikawa","year":"2020","unstructured":"Morikawa, K. et al. Hypothesis generative head-to-head study comparing efficacy of afatinib and osimertinib based on immunological biomarkers in Japanese NSCLC patients with EGFR mutations (Heat on Beat study). Ther. Adv. Med. Oncol. 12, 1758835920967254 (2020).","journal-title":"Ther. Adv. Med. Oncol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-38944-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-38944-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-38944-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T12:34:07Z","timestamp":1772800447000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-38944-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,11]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["38944"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-38944-3","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,11]]},"assertion":[{"value":"17 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Kei Morikawa: personal fees as honoraria from AstraZeneca, Boehringer Ingelheim, Chugai Pharmaceutical, Eli Lilly, Takeda Pharmaceutical; Hisashi Tanaka: personal fees as honoraria from Ono Pharmaceutical, Bristol Myers Squibb, AstraZeneca, Chugai Pharmaceutical, Boehringer Ingelheim, and Pfizer; Yoshitaka Seki: personal fees as honoraria from AstraZeneca, Eli Lilly, MSD, Ono Pharmaceutical, Novartis, Taiho Pharmaceutical, Chugai Pharmaceutical, Boehringer Ingelheim, Shionogi, Sanofi, Kyowa Kirin, Kyorin Pharmaceutical, and GSK; Nagio Takigawa: personal fees as honoraria from Boehringer-Ingelheim Japan, Chugai Pharmaceutical, Eli Lilly Japan, Ono Pharmaceutical, AstraZeneca, Bristol-Myers Squibb Company Japan, Daiichi-Sankyo Pharmaceutical, Taiho Pharmaceutical, Pfizer Inc. Japan, Nippon Kayaku Co. Ltd., Takeda Pharmaceutical Co. Ltd., MSD, and Kyowa Hakko Kirin. Kazuma Kishi: research funding and personal fees as honoraria from Boehringer Ingelheim; Yusuke Okuma: research funding, advisory fee, and personal fees as honoraria from AstraZeneca; research funding from AbbVie and Merck Sharp & Dohme; and personal fees as honoraria from and Chugai Pharmaceutical, Eisai, Eli Lilly, MSD, Ono Pharmaceutical, Takeda Pharmaceutical, and Taiho Pharmaceutical; Akira Togashi: employee of Boehringer Ingelheim; Nobuhiko Seki: research funding and personal fees as honoraria from Eli Lilly, Ono Pharmaceutical, Boehringer Ingelheim, Taiho Pharmaceutical, Chugai Pharmaceutical, Takeda Pharmaceutical, Nippon Kayaku, Pfizer, and Daiichi Sankyo; research funding from Eisai and Shionogi; and personal fees as honoraria from AstraZeneca, MSD, Bristol Myers Squibb, Novartis, and Kyowa Kirin. No potential conflicts of interest were disclosed by the other authors.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"8316"}}